Leukemia

The risk of progression or death was statistically significantly reduced with the use of ibrutinib and venetoclax versus chlorambucil plus obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.

Data presented at 2021 ASCO indicated that chimeric antigen receptor therapy with ALLO-501A plus ALLO-647 lymphodepletion showed promise in patients with relapsed/refractory large B-cell lymphoma.

Phase 1 data presented at 2021 EHA indicate that a high rate of response was associated with zandelisib plus zanubrutinib therapy in patients with relapsed/refractory B-cell malignancies and chronic lymphocytic leukemia.

Data from EHA 2021 showed that zanubrutinib was associated with better outcomes over ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

The combination treatment produced complete responses in more than half of the patients included in the phase 2 CAPTIVATE study.

While survival rates were similar, acalabrutinib had lower rates of atrial fibrillation and other adverse events than ibrutinib for previously treated CLL.

Results of a phase 1/2 trial presented at the 2021 ASCO Annual Meeting show the feasibility of an approach targeting CLL-1 cells in pediatric patients with relapsed or refractory acute myeloid leukemia.

Most patients with either mantle cell lymphoma or chronic lymphocytic leukemia who were treated in a phase 1/2 trial had a response to therapy with the combination of cirmtuzumab plus ibrutinib.

Median progression-free and overall survival in patients with CLL/SLL receiving ibrutinib in the frontline still not reached at 7-year follow-up, according to data from RESONATE-2 trial reported at the 2021 ASCO Annual Meeting.

Successful treatment of patients with Philadelphia chromosome–positive acute lymphocytic leukemia was noted with ponatinib plus blinatumomab, denoted by complete and major molecular responses.

According to new research, patients with chronic lymphocytic leukemia may have suboptimal antibody-mediated response with COVID-19 vaccination.

Most elderly patients with acute myeloid leukemia and myelodysplastic syndromes cannot undergo intensive chemotherapy, but more than half of the patients in a new study responded to a regimen of ultra low–dose decitabine and low-dose cytarabine with G-CSF.

Investigators successfully established the phase 2 dose of APVO436 for patients with acute myeloid leukemia or myelodysplastic syndrome after an acceptable safety profile was achieved in patients with responses to therapy.

A phase 2 trial evaluated the combination of vemurafenib plus rituximab, which produced a complete response in 87% of the evaluable patients with hairy-cell leukemia.

Based on phase 3 data supporting the use of ublituximab in combination with umbralisib versus an existing standard-of-care regimen for chronic lymphocytic leukemia and small cell lymphoma, the FDA has moved forward with a review of the application for approval.

The interim activity and safety data observed were positive for both FT516 and FT538 monotherapy for patients with relapsed or refractory acute myeloid leukemia.

MB-106, a CD20-targeted CAR T-cell therapy that has shown promise in the treatment of B-cell non-Hodgkin lymphoma, is now being considered for patients with relapsed or refractory CD20-positive chronic lymphocytic leukemia.

Reducing caloric and nutrient intake for patients who were overweight or obese and undergoing induction for B-cell acute lymphoblastic leukemia was feasible and improved patient response, according to an early-phase trial.

A retrospective study evaluating over 3.9 million children found that Down syndrome was a strong risk factor for the development of childhood leukemia and has a stronger association with acute myeloid leukemia than previously recorded.

Data in the Journal of Clinical Oncology found that low-intensity chemotherapy without additional intensified pegaspargase cured almost all patients treated on the Children’s Oncology Group AALL0331 trial.

The interim analysis showed positive response and safety data in adult patients with relapsed or refractory CLL or SLL treated with zanubrutinib compared with those receiving ibrutinib.

A phase 2 trial found that acalabrutinib may present a potential therapeutic option for patients with chronic lymphocytic leukemia who discontinued ibrutinib treatment.

Data from Nature Communications detailed MutaSeq, a new method for distinguishing between cancer stem cells, mature stem cells, and healthy stem cells in acute myeloid leukemia.

The selective MCL-1 inhibitor AMG 176 plus gilteritinib as a combination treatment synergistically targeted preclinical models of FLT3 internal tandem duplication–mutated acute myeloid leukemia.

CD19-directed CAR T-cell therapy brexucabtagene autoleucel will be considered by FDA for indication in adults with B-cell precursor acute lymphoblastic leukemia.